FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308402864> ?p ?o ?g. }

• W4308402864 abstract "<h3>Background</h3> VG161 is a novel HSV-1 oncolytic virus expressing IL-12, IL-15, IL-15 receptor alpha subunit isoform 1 (IL-15Rα), and a PD-1/PD-L1 blocking peptide (TF-Fc). This is to report the preliminary clinical and translational data from 11 efficacy evaluable patients. <h3>Methods</h3> In this multicenter phase I trial, we enrolled 11 patients with advanced primary liver cancer refractory to standard therapy including immune checkpoint inhibitor (ICI). VG161 was administrated by imaging guided intra-tumoral injection. Based on preclinical NOAEL, the initial dose level was 1×10⁸ PFU/subject, followed with 4 cohorts (1×10⁸, QD for D1 and D2; 1×10⁸, QD for D1-3; 1.3×10⁸, QD for D1-3; and 1.7×10⁸, QD for D1-3). Fast titration design was used for the first 2 cohorts and followed by standard 3 + 3 design. For PK and viral shedding, virus DNA was measured in blood, urine, oral and injection site swabs by a validated PCR test. Changes of cytokines and lymphocyte subsets in blood was also measured. Antitumor activity was assessed by RECIST1.1 and iRECIST. Overall survival (OS) was recorded. <h3>Results</h3> Eleven patients (aged from 43-74, 9 males and 2 females; 8 HCC and 3 ICC) were enrolled between April 2021 and January 2022. By 10 May 2022, all patients had at least one tumor assessment. No dose limiting toxicity (DLT) was observed. The most common treatment related adverse event (TRAE) was fever (100%). No dose limiting toxicity (DLT) was observed. One serious adverse events (SAEs), Grade 2 sub-facial paralysis (33.3%) was seen in 1 patient, which is related to study drug, no immune-related adverse events (irSAEs) occurred. One ICC patient in 3rd cohort (9%) had immune partial response (iPR) with PFS of 5.3 month based on both iRECIST and RECIST 1.1. Another 2 patients with HCC in the 1st and 2nd cohort had prolonged PFS of 3.7 and 11.5 months respectively. The levels of each T cell immune-related parameter including PD-L1, PD-1, CD69 and CD8+Ki67^high of subjects in each cohort showed an increasing trend after VG161 administration. To date, the median follow-up time is 7.8(2.3-15.6), significantly prolonged OS was seen in 5 patients received ICI after the trial (p=0.025). <h3>Conclusions</h3> Image guided IT injection of VG161 up to 3 times of 1.7×10⁸ PFU/subject was safe and well tolerated, with no unexpected viral spread or shedding. The efficacy of prolonged PFS in 3 patients and PR in 1 patient is encouraging and needs to be further investigated. Clinical trial information: NCT04806464. <h3>Trial Registration</h3> NCT04806464 <h3>Ethics Approval</h3> The study was approved by the Ethics Committee of the First Affiliated Hospital, School of Medicine, Zhejiang University, approval number 20191101. <h3>Consent</h3> Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal." @default.
• W4308402864 created "2022-11-11" @default.
• W4308402864 creator A5004969274 @default.
• W4308402864 creator A5009327702 @default.
• W4308402864 creator A5012544489 @default.
• W4308402864 creator A5016159572 @default.
• W4308402864 creator A5017541508 @default.
• W4308402864 creator A5017738658 @default.
• W4308402864 creator A5019552807 @default.
• W4308402864 creator A5019875964 @default.
• W4308402864 creator A5028780966 @default.
• W4308402864 creator A5039295714 @default.
• W4308402864 creator A5043001105 @default.
• W4308402864 creator A5045117751 @default.
• W4308402864 creator A5053760178 @default.
• W4308402864 creator A5064591852 @default.
• W4308402864 creator A5068984301 @default.
• W4308402864 creator A5075189232 @default.
• W4308402864 creator A5079081217 @default.
• W4308402864 creator A5080892094 @default.
• W4308402864 creator A5083024618 @default.
• W4308402864 creator A5090423848 @default.
• W4308402864 date "2022-11-01" @default.
• W4308402864 modified "2023-10-14" @default.
• W4308402864 title "694 An open-label phase I dose-escalation clinical trial to evaluate the safety, tolerability, pharmacokinetic profile and preliminary efficacy of VG161 in patients with advanced primary liver cancer" @default.
• W4308402864 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0694" @default.
• W4308402864 hasPublicationYear "2022" @default.
• W4308402864 type Work @default.
• W4308402864 citedByCount "0" @default.
• W4308402864 crossrefType "proceedings-article" @default.
• W4308402864 hasAuthorship W4308402864A5004969274 @default.
• W4308402864 hasAuthorship W4308402864A5009327702 @default.
• W4308402864 hasAuthorship W4308402864A5012544489 @default.
• W4308402864 hasAuthorship W4308402864A5016159572 @default.
• W4308402864 hasAuthorship W4308402864A5017541508 @default.
• W4308402864 hasAuthorship W4308402864A5017738658 @default.
• W4308402864 hasAuthorship W4308402864A5019552807 @default.
• W4308402864 hasAuthorship W4308402864A5019875964 @default.
• W4308402864 hasAuthorship W4308402864A5028780966 @default.
• W4308402864 hasAuthorship W4308402864A5039295714 @default.
• W4308402864 hasAuthorship W4308402864A5043001105 @default.
• W4308402864 hasAuthorship W4308402864A5045117751 @default.
• W4308402864 hasAuthorship W4308402864A5053760178 @default.
• W4308402864 hasAuthorship W4308402864A5064591852 @default.
• W4308402864 hasAuthorship W4308402864A5068984301 @default.
• W4308402864 hasAuthorship W4308402864A5075189232 @default.
• W4308402864 hasAuthorship W4308402864A5079081217 @default.
• W4308402864 hasAuthorship W4308402864A5080892094 @default.
• W4308402864 hasAuthorship W4308402864A5083024618 @default.
• W4308402864 hasAuthorship W4308402864A5090423848 @default.
• W4308402864 hasBestOaLocation W43084028641 @default.
• W4308402864 hasConcept C112705442 @default.
• W4308402864 hasConcept C121608353 @default.
• W4308402864 hasConcept C126322002 @default.
• W4308402864 hasConcept C143998085 @default.
• W4308402864 hasConcept C197934379 @default.
• W4308402864 hasConcept C2778375690 @default.
• W4308402864 hasConcept C29730261 @default.
• W4308402864 hasConcept C535046627 @default.
• W4308402864 hasConcept C71924100 @default.
• W4308402864 hasConcept C82210918 @default.
• W4308402864 hasConcept C90924648 @default.
• W4308402864 hasConcept C98274493 @default.
• W4308402864 hasConceptScore W4308402864C112705442 @default.
• W4308402864 hasConceptScore W4308402864C121608353 @default.
• W4308402864 hasConceptScore W4308402864C126322002 @default.
• W4308402864 hasConceptScore W4308402864C143998085 @default.
• W4308402864 hasConceptScore W4308402864C197934379 @default.
• W4308402864 hasConceptScore W4308402864C2778375690 @default.
• W4308402864 hasConceptScore W4308402864C29730261 @default.
• W4308402864 hasConceptScore W4308402864C535046627 @default.
• W4308402864 hasConceptScore W4308402864C71924100 @default.
• W4308402864 hasConceptScore W4308402864C82210918 @default.
• W4308402864 hasConceptScore W4308402864C90924648 @default.
• W4308402864 hasConceptScore W4308402864C98274493 @default.
• W4308402864 hasLocation W43084028641 @default.
• W4308402864 hasOpenAccess W4308402864 @default.
• W4308402864 hasPrimaryLocation W43084028641 @default.
• W4308402864 hasRelatedWork W2037576960 @default.
• W4308402864 hasRelatedWork W2074207917 @default.
• W4308402864 hasRelatedWork W2080612540 @default.
• W4308402864 hasRelatedWork W2154883587 @default.
• W4308402864 hasRelatedWork W2914758292 @default.
• W4308402864 hasRelatedWork W4205587618 @default.
• W4308402864 hasRelatedWork W4253098345 @default.
• W4308402864 hasRelatedWork W4296087748 @default.
• W4308402864 hasRelatedWork W4366822339 @default.
• W4308402864 hasRelatedWork W1962564742 @default.
• W4308402864 isParatext "false" @default.
• W4308402864 isRetracted "false" @default.
• W4308402864 workType "article" @default.